Teva removes over 200 improper patent listings under pressure from US FTC
MLex Summary: Teva Pharmaceuticals has requested that the US Food and Drug Administration remove more than 200 improper patent listings from the FDA’s Orange Book following a challenge from the Federal...To view the full article, register now.
Already a subscriber? Click here to view full article